Novartis reports positive lung cancer trial data for Zykadia

Novartis has announced new phase III clinical trial data showing the safety and effectiveness of Zykadia in the treatment of certain forms of lung cancer.

Top-line results from the ASCEND-4 clinical study showed that Zykadia met its primary endpoint in the trial, which was conducted among patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.

Clinically significant improvements in progression-free survival rates were observed in previously untreated adult patients when compared to standard chemotherapy, including maintenance.

Meaningful results were also achieved across several key secondary efficacy measures, including objective response rate and duration of response, while adverse events were consistent with the previously known profile of Zykadia.

A full analysis of the ASCEND-4 data containing detailed efficacy and safety results will now be submitted for presentation at a major medical congress.

Alessandro Riva, global head for oncology development and medical affairs at Novartis Oncology, said: "We are pleased to see these topline results show promise in untreated patients with advanced disease, and look forward to sharing these data with regulatory authorities in the coming months."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.